The endless frontier? The recent increase of R&D productivity in pharmaceuticals

作者
Fabio Pammolli A,Lorenzo Righetto,Sergio Abrignani,Luca Pani,Pier Giuseppe Pelicci,Emanuele Rabosio
出处
期刊:Journal of Translational Medicine [BioMed Central]
卷期号:18 (1): 162-162 被引量:77
标识
DOI:10.1186/s12967-020-02313-z
摘要

BACKGROUND: Studies on the early 2000s documented increasing attrition rates and duration of clinical trials, leading to a representation of a "productivity crisis" in pharmaceutical research and development (R&D). In this paper, we produce a new set of analyses for the last decade and report a recent increase of R&D productivity within the industry. METHODS: We use an extensive data set on the development history of more than 50,000 projects between 1990 and 2017, which we integrate with data on sales, patents, and anagraphical information on each institution involved. We devise an indicator to quantify the novelty of each project, based on its set of mechanisms of action. RESULTS: First, we investigate how R&D projects are allocated across therapeutic areas and find a polarization towards high uncertainty/high potential reward indications, with a strong focus on oncology. Second, we find that attrition rates have been decreasing at all stages of clinical research in recent years. In parallel, for each phase, we observe a significant reduction of time required to identify projects to be discontinued. Moreover, our analysis shows that more recent successful R&D projects are increasingly based on novel mechanisms of action and target novel indications, which are characterized by relatively small patient populations. Third, we find that the number of R&D projects on advanced therapies is also growing. Finally, we investigate the relative contribution to productivity variations of different types of institutions along the drug development process, with a specific focus on the distinction between the roles of Originators and Developers of R&D projects. We document that in the last decade Originator-Developer collaborations in which biotech companies act as Developers have been growing in importance. Moreover, we show that biotechnology companies have reached levels of productivity in project development that are equivalent to those of large pharmaceutical companies. CONCLUSIONS: Our study reports on the state of R&D productivity in the bio-pharmaceutical industry, finding several signals of an improving performance, with R&D projects becoming more targeted and novel in terms of indications and mechanisms of action.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
sujinyu完成签到,获得积分10
刚刚
healer发布了新的文献求助10
刚刚
1秒前
kgy完成签到,获得积分10
1秒前
2秒前
2秒前
alexstu完成签到,获得积分10
3秒前
iQ完成签到,获得积分10
3秒前
lllchulin的应助被红颜刹朱槿采纳,获得10
3秒前
老师来了完成签到,获得积分10
3秒前
4秒前
麕麕完成签到 ,获得积分10
5秒前
ygj发布了新的文献求助10
5秒前
5秒前
mayucong完成签到,获得积分0
5秒前
5秒前
陈老派发布了新的文献求助10
6秒前
6秒前
烟花的应助被Qianfan采纳,获得10
6秒前
6秒前
酷波er的应助被野酒采纳,获得10
6秒前
寒烟完成签到,获得积分10
6秒前
胖头鱼发布了新的文献求助10
6秒前
9秒前
10秒前
白白不是球完成签到,获得积分10
10秒前
yyyyy发布了新的文献求助30
10秒前
害怕的穆发布了新的文献求助10
10秒前
chilin发布了新的文献求助10
11秒前
Maestro_S的应助被神奇蜥蜴采纳,获得10
11秒前
无极微光的应助被烂漫的灰狼采纳,获得20
11秒前
王海祥完成签到 ,获得积分10
12秒前
包容的飞丹完成签到,获得积分10
13秒前
chcuifv完成签到 ,获得积分10
13秒前
快乐如云朵完成签到 ,获得积分10
13秒前
RichardGuo完成签到 ,获得积分10
13秒前
李健的小迷弟的应助被hepote采纳,获得10
13秒前
友好小刺猬完成签到,获得积分10
14秒前
六六完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463